NCT04796324 2026-03-12
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Allarity Therapeutics
Phase 2 Terminated
Clinical Trials
46 trialsNCT00877500 2025-11-10
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01349088 2025-05-02
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
Thomas Jefferson University
Phase 1/2 Withdrawn
NCT00630032 2024-02-21
TavIx
UNICANCER
Phase 3 Completed
NCT00765765 2023-08-09
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT00879086 2023-06-22
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT02067416 2023-02-02
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT01446016 2023-01-23
CAT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00785291 2022-10-10
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00866905 2021-11-22
Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01097642 2021-09-22
ICE
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00080301 2020-11-02
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
R-Pharm
Phase 3 Completed
NCT00082433 2020-11-02
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
R-Pharm
Phase 3 Completed
NCT01818999 2020-08-20
Ixabepilone and SBRT For Metastatic Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT01084057 2019-11-05
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Completed
NCT01416389 2019-09-18
A Study of LY2523355 in Participants With Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00005807 2018-10-09
BMS-247550
Albert Einstein College of Medicine
Phase 1 Completed
NCT00627978 2018-06-26
Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons
Weill Medical College of Cornell University
Phase 2 Completed
NCT01012362 2017-12-28
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00789581 2017-07-02
TITAN
SCRI Development Innovations, LLC
Phase 3 Completed
NCT00637897 2017-05-30
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT00049244 2017-01-30
BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer
R-Pharm
Phase 1 Unknown
NCT00080262 2017-01-30
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
R-Pharm
Phase 2 Completed
NCT01027208 2017-01-30
A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline
R-Pharm
Phase 2 Completed
NCT01075100 2016-12-07
Ixabepilone + Carboplatin Metastatic Breast Cancer
US Oncology Research
Phase 2 Completed
NCT00182767 2016-03-10
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00322374 2016-03-10
Phase I Combination w/ Epirubicin
R-Pharm
Phase 1 Completed
NCT00370552 2016-03-10
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
R-Pharm
Phase 2 Completed
NCT00490646 2016-03-10
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
R-Pharm
Phase 2 Completed
NCT00546364 2016-03-10
IXTEND
R-Pharm
Phase 2 Terminated
NCT00568022 2016-03-10
A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
R-Pharm
Phase 1 Completed
NCT00593827 2016-03-10
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
R-Pharm
Phase 2 Completed
NCT00633464 2016-03-10
Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer
R-Pharm
Phase 2 Completed
NCT00634088 2016-03-10
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
R-Pharm
Phase 1 Terminated
NCT00455533 2016-02-24
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00998738 2016-02-04
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
Mayo Clinic
Phase 3 Terminated
NCT00821886 2014-12-22
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00825734 2014-12-22
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00751868 2014-12-17
GIM9
Consorzio Oncotech
Phase 2 Completed
NCT00924352 2014-10-13
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Accelerated Community Oncology Research Network
Phase 1/2 Completed
NCT00079326 2014-06-02
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00077376 2014-05-21
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00045097 2013-06-20
Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00020904 2013-06-18
BMS-247550 in Treating Women With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00790894 2011-05-18
HIT
Hellenic Cooperative Oncology Group
Phase 2 Terminated